









Markets
/
Stocks
/
nasdaq-acet
/

Adicet Bio Inc

ACET

7.030USD

+0.590+9.16%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

36.58MMarket Cap

LossP/E TTM



Adicet Bio Inc

7.030

+0.590+9.16%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Adicet Bio Inc

Currency: USD Updated: 2026-02-06

Key Insights

Adicet Bio Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 129 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 61.50.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Adicet Bio Inc's Score

Industry at a Glance

Industry Ranking

129 / 392

Overall Ranking

267 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Adicet Bio Inc Highlights

StrengthsRisks

Adicet Bio, Inc. is a clinical-stage biotechnology company. It is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases. ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Its pipeline also includes ADI-270, an investigational allogeneic gamma delta CAR T cell therapy targeting CD70 via the CD27-ligand for the treatment of RCC and with potential in other solid tumor and hematological malignancy indications. Its pipeline has additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -0.35, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 55.73M shares, increasing 8.23% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 114.31K shares of this stock.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

61.500

Target Price

+854.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Adicet Bio Inc is 6.43, ranking 256 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

6.43

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.41

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.93

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Adicet Bio Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Adicet Bio Inc is 7.10, ranking 174 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.35, which is -8.38% below the recent high of -0.32 and -1907.60% above the recent low of -7.00.

Score

Industry at a Glance

Previous score

7.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 129/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Adicet Bio Inc is 8.86, ranking 43 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 9.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.86

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

61.500

Target Price

+854.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Adicet Bio Inc

ACET

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Adicet Bio Inc is 6.88, ranking 144 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.55 and the support level at 5.96, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.46

Change

0.42

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.288

Sell

RSI(14)

38.172

Neutral

STOCH(KDJ)(9,3,3)

15.184

Oversold

ATR(14)

0.533

High Vlolatility

CCI(14)

-171.427

Sell

Williams %R

75.962

Sell

TRIX(12,20)

-0.269

Sell

StochRSI(14)

59.516

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

7.316

Sell

MA10

7.876

Sell

MA20

8.011

Sell

MA50

8.258

Sell

MA100

9.182

Sell

MA200

4.942

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Adicet Bio Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 45.53%, representing a quarter-over-quarter decrease of 46.82%. The largest institutional shareholder is The Vanguard, holding a total of 291.28K shares, representing 3.04% of shares outstanding, with 21.57% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

OrbiMed Advisors, LLC

11.45M

Tang Capital Management, LLC

8.22M

RA Capital Management, LP

7.54M

The Vanguard Group, Inc.

Star Investors

3.27M

+2.08%

Goldman Sachs & Company, Inc.

3.75M

-0.00%

Abingworth Management Limited

2.95M

Acadian Asset Management LLC

2.07M

+1.73%

Renaissance Technologies LLC

Star Investors

1.15M

+42.32%

Two Sigma Investments, LP

1.08M

-3.49%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Adicet Bio Inc is 1.29, ranking 329 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.58. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.